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Introduction
Sorafenib and sunitinib, which are multikinase inhibitors
of tumor-cell proliferation and angiogenesis, have been
shown to have some activity in 2 double-blinded,
placebo-controlled trials in patients with metastatic
renal cell carcinoma (RCC).1,2 All of the patients’ his-
tology results were clear cell cancer. There are currently
no studies showing that sorafenib and sunitinib are also
effective in metastatic RCC other than clear cell histo-
logic components. We report a case where sorafenib was
used in a patient with metastatic RCC with sarcomatoid
differentiation.
Case Report
A 38-year-old male with metastatic RCC presented
with developing progressive disease after standard
interleukin (IL)-2 and interferon-α (IFN-α) therapy.
A computed tomography (CT) scan of the abdomen
demonstrated a 73 × 65-mm left-sided renal mass and
a 15-mm mass with perifocal edema in the parietal
lobe of the brain. We also observed multiple metastatic
nodules in both lung parenchyma (Figures 1–3). Left
radical nephrectomy had been performed in October
2005. Pathological examination revealed clear cell
carcinoma with diffuse sarcomatoid differentiation.
Fuhrman’s grade was III. Pathological staging was T3
and the surgical margin was positive. The lymph nodes
and adrenal glands were not invaded (Figures 4 and 5).
Postoperative radiotherapy for intracranial metasta-
sis and edema was applied immediately. A total of 30Gy
radiotherapy in 10 fractions within each 3 Gy was given
to whole brain sections. In January 2006, regression
was observed in both intracranial diameters of the mass
and edema. Thereafter, immunotherapy consisting of
IL-2 and IFN-α was administered to the patient for 
8 weeks (20 MU/day, 3–5 days per week IFN-α
and 72,000 IU/kg IL-2). Unfortunately, during re-
evaluation, no response was observed, but a new mass
was detected in the left renal fossa.
We decided that targeted therapy with sorafenib
was the last chance of treatment for this patient. In April
2006, the patient started treatment with sorafenib given
orally at a dose of 400 mg twice a day as recommended
by Kroog and Motzer.3 At the 6-month follow-up,
the patient was alive and a total body CT scan showed
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no evidence of clinical progression. An abdomen and
thorax CT revealed no metastatic focus in both the
left renal fossa and lung parenchyma.
Unfortunately, the patient died because of disease
progression, with multiple metastases 22 months from
the first diagnosis, even though there was a complete
response with disappearance of all tumoral deposits
demonstrated at the 6-month follow-up after the first
diagnosis. However, we obtained 22 months of survi-
val advantage for this patient. The patient had a slight
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Figure 1. (A) Preoperative abdominal computed tomography shows a left-sided renal mass. (B) Postoperative abdominal computed
tomography.
Figure 2. (A) Multiple lung metastases. (B) No metastasis after treatment.
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Figure 3. Radical nephrectomy specimen. Figure 4. Clear cell carcinoma with sarcomatoid differentiation
(hematoxylin & eosin, 100×).
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hand and foot syndrome due to toxicity of the drug.
He needed no additional drugs for this complication.
Discussion
RCC is the most aggressive and lethal genitourinary can-
cer, with more than 40% of patients dying of cancer.4
Unfortunately, no reliable treatment alternative has yet
been developed for metastatic RCC. Recently, inves-
tigations in targeted therapy including multikinase
inhibition and antiangiogenesis have been encourag-
ing to clinicians in that they have some activity in the
management of metastatic RCC. Overall, progression-
free survival advantages with targeted therapy was
demonstrated in 2 double-blinded, placebo-controlled
studies in the treatment of metastatic disease.1,2 Never-
theless, there are still many unanswered questions. The
response rate in different histological types is not clear.
We administered sorafenib in a patient with metastatic
RCC with sarcomatoid differentiation and obtained
an excellent result.
This case report provides evidence that certain
antiangiogenic agents may be active in renal cancers
of cell types other than those with clear cell histology.
Additional data on the durability of the response may
further clarify the complete response and survival
benefit.
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Figure 5. Left parietal mass and peripheral edema.
